U.S. Markets close in 9 mins

Terumo Corporation (TRUMY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
36.83-0.51 (-1.37%)
As of 2:39PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close37.35
Open37.13
Bid0.00 x 0
Ask0.00 x 0
Day's Range36.75 - 37.42
52 Week Range25.80 - 42.16
Volume4,519
Avg. Volume16,139
Market Cap27.613B
Beta (5Y Monthly)0.46
PE Ratio (TTM)16.51
EPS (TTM)2.23
Earnings DateN/A
Forward Dividend & Yield0.26 (0.70%)
Ex-Dividend DateMar 27, 2020
1y Target EstN/A
  • IceCure Expands Strategic Collaboration with Terumo: New Commercial Distribution Agreement Potentially Valued at over $7.0 Million
    PR Newswire

    IceCure Expands Strategic Collaboration with Terumo: New Commercial Distribution Agreement Potentially Valued at over $7.0 Million

    IceCure Medical Ltd. (TASE: ICCM), developer of the next generation cryoablation technology that destroys tumors by freezing without the need for surgery, today announced that it has expanded its strategic partnership with Terumo Corporation (Tokyo: 4543) (TRUMY: OTC US), a leading Japanese medical devices company with a global footprint. The expanded partnership reflects the ongoing success of the initial agreement, which was signed in September 2019, and included distribution rights in Japan and Singapore. The new multi-million dollar agreement, which is expected to be finalized by the end of the year, will grant Terumo exclusive rights to distribute IceCure's products in Thailand for six years, with an option to extend the agreement for an additional six years.

  • MicroVention-Terumo Announces New Leadership
    PR Newswire

    MicroVention-Terumo Announces New Leadership

    MicroVention, Inc., a U.S. based subsidiary of Terumo and leading global neurovascular company, announced today the appointment of a new President and CEO, Mr. Carsten Schroeder. The MicroVention acting President and CEO, Kazuaki Kitabatake, who has been in his role since August 2019, will continue as Chairman of the Board for MicroVention. Mr. Schroeder will assume this position with MicroVention in early November 2020.

  • Terumo Cardiovascular and CytoSorbents Collaborate to Commercialize CytoSorb® in Ten U.S. Hotspot States under Emergency Use Authorization for COVID-19
    PR Newswire

    Terumo Cardiovascular and CytoSorbents Collaborate to Commercialize CytoSorb® in Ten U.S. Hotspot States under Emergency Use Authorization for COVID-19

    Terumo Cardiovascular, a global leader in cardiovascular surgery technologies and subsidiary of Japan-based Terumo Corporation (TSE: 4543), and CytoSorbents Corporation (NASDAQ: CTSO), manufacturer of the CytoSorb® extracorporeal cytokine adsorber, announced an initial collaboration to exclusively sell CytoSorb to hospitals in ten U.S. COVID-19 hotspot states including Alabama, Arizona, California, Georgia, Louisiana, Mississippi, New Mexico, Oregon, Texas, and Washington. CytoSorb previously received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for use in adult, critically-ill COVID-19 patients with imminent or confirmed respiratory failure.